SCHEMBL3587549

SCHEMBL3587549

CCC1c2ccc(Cl)cc2S(=O)(=O)NN1CC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 5/20 0.39
GRIA1 P42261 4/20 0.39
GRIA3 P42263 4/20 0.39
GRIA4 P48058 4/20 0.39
CA2 P00918 3/20 0.38
CA12 O43570 2/20 0.38
CA4 P22748 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CHEK1 O14757 1/20 0.38
DAPK3 O43293 1/20 0.38
MAP4K4 O95819 1/20 0.38
RET P07949 1/20 0.38
PIM1 P11309 1/20 0.38
LTK P29376 1/20 0.38
GRK5 P34947 1/20 0.38
CSNK1A1 P48729 1/20 0.38
CDK8 P49336 1/20 0.38
PRKX P51817 1/20 0.38
LIMK1 P53667 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3583177 0.81 CA2 (0.37) GRIA2GRIA1GRIA3GRIA4CA2
SCHEMBL3575925 0.70 ALDH1A1 (0.40) GRIA2GRIA1GRIA3GRIA4CA2
SCHEMBL3588752 0.64 ALDH1A1 (0.46) GRIA2GRIA1GRIA3GRIA4CA2
SCHEMBL2791341 0.61 ALDH1A1 (0.37) GRIA2GRIA1GRIA3GRIA4CA2
SCHEMBL3578225 0.60 CA2 (0.46) GRIA2GRIA1GRIA3GRIA4CA2
SCHEMBL13753857 0.57 CA2 (0.41) CA2CA12CA4CA7CA9
SCHEMBL8891388 0.57 CA12 (0.61) GRIA2GRIA1GRIA3GRIA4CA2
SCHEMBL5917510 0.57 GRIA2 (0.63) GRIA2GRIA1GRIA3GRIA4CA2
SCHEMBL23191245 0.56 GRIA2 (0.46) GRIA2GRIA1GRIA3GRIA4CA2
SCHEMBL3984666 0.56 RET (1.00) CA2CA12CA4CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENTARSASAG (HU) 2010-07-29 US disclosed
EP-2064197-A2 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE Egis Gyogyszergyar Nyilvánosan Múködó Részvénytársaság (HU) 2009-06-03 EP disclosed
WO-2008020256-A2 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE EGIS GYÓGYSZERGYÁR_Nyilvánosan Müködö Részvénytársaság (HU) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190778-A1 3,4-DIHYDROBENZO[1,2,3]THIADIAZINE-1,1-DIOXIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, MEDICAMENTS CONTAINING SAID DERIVATIVES AND THEIR USE TDO2, DHODH, DHPS GRIA2 1224/4885GRIA1 1215/4885GRIA3 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.